To the central content area :::
:::Listed Companies > Listed Companies Info. > Main Board Companies > Listed Company Profile

General Stock Board Listed Company Profile

6733 BioGend
Company Profile
Chairman CEO Spokesperson Tel Address Date of Listing (Regular)
Te Li Chen Te Li Chen Byron Chao 02-26558366 4F, No.3-2, Yuang St.Nangang DistrictTaipei City, Taiwan, R.O.C. 2021/01/28
Industry Main Business
Biotechnology and Medical Care BioGend Therapeutics was established in July 2016 with a noble vision to develop regenerative bio-orthopedic medicine to advance the clinical science of maintaining healthy joints in the skeletal system. We are committed to developing innovative bio-orthopedic devices and treatment methods that can fulfill unmet clinical needs benefiting patients worldwide. The project management teams at BioGend Therapeutics are led by seasoned product development managers with team members from different functional areas. Each development project is carefully planned to follow the phase-gate process for effective and efficient execution. For highly regulated biomedical devices, the expertise in regulatory affairs and pre-clinical and clinical development is essential in order to gain regulatory approval and to realize the potential value of innovative bio-technologies.
Market Information ( 2024/06/17 )
Shr. Vol. Highest Lowest Closed Change Transaction TurnOver(%) long
366.254 37.30  36.00  36.85  0.60  208 .00 N/A N/A
Trading method Fun
price or
on T day
Announcement of Irregularity
TPEx measures
With warrants Can be shorted or margined? Detail
Normal N N N N N Today History
Financial Reports
Cash Flows Items
(NT$ thousand)
Cash flows from operating activities
Cash flows from investing activities
Cash flows from financing activities
Current assets
Non-current assets
Total assets
Current liabilities
Non-current liabilities
Total liabilities
Share capital
Capital surplus
Retained earnings
Other equity interest
Treasury shares
Total equity attributable to owners of parent
Non-controlling interests
Total equity
Book Value per share(NT$)
Comprehensive Income Operating revenue
Operating costs
Gross profit from operations
Operating expenses
Net other income (expenses)
Net operating income
Non-operating income and expenses
Profit before tax
Tax expense
Profit from continuing operations
Profit from discontinued operations
Other comprehensive income
Comprehensive income
Basic earnings per share
 Auditor's report on latest financial statements: auditor's report:
 More detail:MOPS
 Foreign issuers’ information is disclosed in consolidated statements.